Pituitary Diseases
Disorders involving either the ADENOHYPOPHYSIS or the NEUROHYPOPHYSIS. These diseases usually manifest as hypersecretion or hyposecretion of PITUITARY HORMONES. Neoplastic pituitary masses can also cause compression of the OPTIC CHIASM and other adjacent structures.
Subtype terms (8)
More specific conditions that are subtypes of Pituitary Diseases in the MeSH hierarchy.
- Diabetes Insipidus
14 drugs (12 approved, 2 experimental)
- Empty Sella Syndrome
- Hyperpituitarism
- Hypophysitis
- Hypopituitarism
18 drugs (14 approved, 4 experimental)
- Inappropriate ADH Syndrome
4 drugs (3 approved, 1 experimental)
- Pituitary Apoplexy
- Pituitary Neoplasms
45 drugs (36 approved, 9 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (4)
Phase 3 trials (7)
Phase 2 trials (3)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (15)
- Merck Serono
- Merck KGaA
- Novartis
- University of Arizona
- Barrow Neurological Institute
- Azienda Ospedaliera San Giovanni Battista
- Mahidol University
- New York University
- Pontificia Universidad Catolica de Chile
- Sichuan University
- Thomas Jefferson University
- University of Rochester
- University of Bologna
- University of Texas, Galveston
- The Moody Foundation
Organization Involved with Phase 3 Indications (17)
- Ipsen
- BioPartners GmbH
- LG
- Duramed Research
- National Institutes of Health (NIH)
- National Institute on Aging (NIA)
- Huazhong University of Science and Technology
- Harvard University
- Norwegian University of Science and Technology
- Assiut University
- Federal University of Rio de Janeiro
- Ascendis Pharma, Inc.
- University of Sao Paulo
- University of Paris
- Sungkyunkwan University
- Chinese Academy of Medical Sciences
- Visen Pharmaceuticals
Organization Involved with Phase 2 Indications (19)
- Morphotek
- Endocyte
- National Cancer Institute (NCI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Central South University
- Burzynski Research Institute
- Cedars-Sinai Medical Center
- Cornell University
- Emory University
- Nanjing University
- Chongqing Medical University
- Columbia University
- Peking University
- University of California, Los Angeles
- Tsinghua University
- University of Texas at Houston
- Memorial Sloan-Kettering Cancer Center
- The University of Texas, Dallas
- Tiburio Therapeutics
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (15)
- Aarhus University
- Seoul National University
- University of Ottawa
- Yonsei University
- Capital Medical University
- Fudan University
- Fujian Medical University
- Istanbul University
- Wenzhou Medical University
- Jiao Tong University
- Washington University in St. Louis
- Department of Veteran Affairs
- Rouen Normandy University
- China Medical University
- People's Liberation Army of China